Related Experiment Video

Updated: Jul 6, 2025

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.6K

Identification of concurrent STAT3::RARA and RARA::STAT5b fusions in a variant APL case

Tingting Tao1,2, Jiannong Cen1,2, Chao Xu1,2

  • 1Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, Department of Haematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, People's Republic of China.

Molecular Carcinogenesis
|December 28, 2023
PubMed

Insights

Variant acute promyelocytic leukemia (APL) can lack the typical PML::RARA fusion. This study identified novel STAT3::RARA and RARA::STAT5b fusions in a resistant APL case, highlighting the need for accurate RARA partner gene detection.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Acute promyelocytic leukemia (APL) is typically characterized by the PML::RARA fusion gene resulting from the t(15;17) translocation.
  • A subset of APL patients lack the canonical t(15;17) translocation and PML::RARA fusion, presenting diagnostic and therapeutic challenges.

Purpose of the Study:

  • To report the identification of novel gene fusions in a variant APL case.
  • To emphasize the importance of detecting RARA gene partners in variant APL.
  • To highlight the urgent need for effective therapeutic strategies for such cases.

Main Methods:

  • Genetic analysis to identify fusion genes in a patient with APL lacking t(15;17)/PML::RARA.
  • Clinical assessment of treatment response to standard chemotherapy.

Main Results:

  • Coexistence of STAT3::RARA and RARA::STAT5b fusions was identified for the first time in a variant APL patient.
  • The patient exhibited resistance to all-trans retinoic acid and arsenic trioxide chemotherapy.

Conclusions:

  • Accurate detection of RARA gene partners is critical for diagnosing and managing variant APL.
  • Novel gene fusions in APL can lead to therapeutic resistance.
  • Development of targeted therapies is urgently required for APL patients with variant fusions.
Keywords:
RARA::STAT5bSTAT3::RARAacute promyelocytic leukemiavariant acute promyelocytic leukemia

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.0K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.0K

Related Concept Videos

Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K